MedTrace Logo

Etanercept in Hidradenitis Suppurativa

NCT00329823 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2006-05-25

No results posted yet for this study

Summary

The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the disease. The objective of this study is to clarify the potency of etanercept for the therapy of hidradenitis suppurativa.

Conditions

Interventions

DRUG

Etanercept sc 50mg per week for 12 weeks

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Evangelos J Giamarellos-Bourboulis, MD, PhD · 4th Department of Internal Medicine, University of Athens, Greece

  • Helen Giamarellou, MD, PhD · 4th Department of Internal Medicine, University of Athens, Greece

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-05-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329823 on ClinicalTrials.gov